TREATMENT OF SEVERE REFRACTORY PEMPHIGUS VULGARIS WITH RITUXIMAB

被引：9

作者：

Pitarch, Gerard ^{[1
]}

Sanchez-Carazo, Jose L. ^{[1
]}

Pardo, Jose ^{[1
]}

Torrijos, Arantxa ^{[1
]}

Roche, Elena ^{[1
]}

Fortea, Jose M. ^{[1
]}

机构：

[1] Hosp Gen Univ Valencia, Serv Dermatol, Avda Tres Cruces S-N, Valencia 46014, Spain

来源：

ACTAS DERMO-SIFILIOGRAFICAS | 2006年 / 97卷 / 01期

关键词：

pemphigus vulgaris; pemphigus foliaceus; rituximab; infliximab;

D O I：

10.1016/S0001-7310(06)73348-8

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Pemphigus vulgaris is a potentially fatal autoimmune bullous disease. High doses of immunosuppressive drugs are used in managing severe cases of pemphigus. Rituximab, an anti-CD20 monoclonal antibody, has proven to be effective in patients with refractory pemphigus vulgaris and pemphigus foliaceus. We review cases of pemphigus vulgaris and pemphigus foliaceus not associated with lymphoma that were treated with rituximab, and we report a new case of severe refractory pemphigus vulgaris successfully treated with rituximab.

引用

页码：48 / 51

页数：4

共 20 条

[1]

Borradori L, 2001, ARCH DERMATOL, V137, P269

[2] Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab) [J].

Cooper, HL ;

Healy, E ;

Theaker, JM ;

Friedmann, PS .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2003, 28 (04) :366-368

[3]

Duchosal MA, 1997, SEMIN HEMATOL, V34, P2

[4] Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody) [J].

Dupuy, A ;

Viguier, M ;

Bédane, C ;

Cordoliani, F ;

Blaise, S ;

Aucouturier, F ;

Bonnetblanc, JM ;

Morel, P ;

Dubertret, L ;

Bachelez, H .

ARCHIVES OF DERMATOLOGY, 2004, 140 (01) :91-96

[5] Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations [J].

España, A ;

Fernández-Galar, M ;

Lloret, P ;

Sánchez-Ibarrola, AF ;

Panizo, C .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (06) :974-976

[6] Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab [J].

Goebeler, M ;

Herzog, S ;

Bröcker, EB ;

Zillikens, D .

BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (04) :899-901

[7]

Heizmann M, 2001, AM J HEMATOL, V66, P142, DOI 10.1002/1096-8652(200102)66:2<142::AID-AJH1032>3.3.CO

[8]

2-S

[9] Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab) [J].

Herrmann, G ;

Engert, A ;

Hunzelmann, N .

BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (03) :602-603

[10] Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab) [J].

Morrison, LH .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (05) :817-819

← 1 2 →